Comparable stake leader
FMR LLC
SEC ownership of OCULAR THERAPEUTIX, INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001393434.
Disclosed value leader
FMR LLC
Comparable rows
6/50
Latest evidence
24 Aug 2026
- Public ticker
- OCUL on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
24 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001393434
- Issuer location
- Bedford, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of OCULAR THERAPEUTIX, INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
6/50
Latest evidence
24 Aug 2026
13D/G
13F
3/4/5
Lead comparable stake: 15%
44 rows are not safely comparable across share classes.
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
Deep Track Capital, LP
9.5%
BlackRock, Inc.
7%
SUMMER ROAD LLC
5.7%
Venrock Healthcare Capital Partne...
3.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
Reported 13D/G
· 30 Sep 2025
|
$371,574,057
31,785,634 shares
|
+$142,354,542 | 30 Sep 2025 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
9.5%
Reported 13D/G
· 31 Mar 2026
|
$193,319,289
19,686,282 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7%
Reported 13D/G
· 30 Jun 2026
|
$190,277,772
19,376,555 shares
|
— | 30 Jun 2026 |
| SUMMER ROAD LLC |
13D/G
3/4/5
13F
10%+ Owner · Company
|
5.7%
Reported 13D/G
· 04 Dec 2025
|
$131,657,773
12,134,357 shares
|
$0 | 04 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
3.2%
Reported 13D/G
· 31 Dec 2025
|
$81,120,329
6,862,972 shares
|
-$71,516,295 | 31 Dec 2025 |
| Opaleye Management Inc. |
13D/G
13F
Company
|
2.8%
Reported 13D/G
· 31 Dec 2024
|
$34,305,750
4,342,500 shares
|
$0 | 31 Dec 2024 |
| Avoro Capital Advisors LLC |
13F
Company
|
—
denominator unverified
|
$123,142,800
12,540,000 shares
|
— | 30 Jun 2026 |
| Venrock Adviser, LLC |
13F
Company
|
—
denominator unverified
|
$101,606,813
10,346,926 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,834,823.
Buys
$461,354
Insiders: 1
Sells
$3,296,177
Insiders: 8
Net
-$2,834,823
Shares: -298,387
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 60,229
Shares: 358,616
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 63,819 | $0 | $567,500 | -$567,500 |
| 3-6 | 0 | 43,827 | $0 | $360,419 | -$360,419 |
| 6-9 | 60,229 | 197,221 | $461,354 | $1,754,805 | -$1,293,450 |
| 9-12 | 0 | 53,749 | $0 | $613,453 | -$613,453 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to OCULAR THERAPEUTIX, INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
SUMMER ROAD LLC
Net 12M change
-$2,834,823
Latest report
08 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| SUMMER ROAD LLC | 10%+ Owner | $64,607,336 | Filing P/S | 26 Feb 2024 | ||
| Pravin Dugel | Executive Chairman, President and CEO, Director | $34,513,817 | -$1,936,777 | -5.3% | Mixed | 24 Aug 2026 |
| Donald Notman | Chief Operating Officer | $3,753,256 | -$216,123 | -5.4% | Filing P/S | 31 Aug 2026 |
| Sanjay Nayak | Chief Strategy Officer | $3,523,960 | -$166,407 | -4.5% | Filing P/S | 24 Aug 2026 |
| Antony C. Mattessich | President and CEO, Director | $2,892,677 | Mixed | 03 Feb 2024 | ||
| Namrata Saroj | Chief Business Officer | $2,774,008 | -$277,790 | -9.1% | Mixed | 02 Jan 2026 |
| Nadia Waheed | Chief Medical Officer | $2,481,653 | -$220,876 | -8.2% | Filing P/S | 03 Jun 2026 |
| Steve Lawrence Meyers | Chief Commercial Officer | $2,370,991 | Mixed | 02 Jan 2026 | ||
| Richard L. Lindstrom MD | Director | $2,210,102 | +$461,354 | +26% | Mixed | 10 Jun 2026 |
| Jeffrey S. Heier | Chief Scientific Officer | $2,167,571 | -$203,984 | -8.6% | Filing P/S | 02 Oct 2026 |
| Peter Kaiser | Chief Development Officer | $1,793,435 | -$186,857 | -9.4% | Filing P/S | 02 Oct 2026 |
| David Wayne Robinson | Global CCO | $1,651,040 | Mixed | 21 Jan 2026 | ||
| Michael H. Goldstein | President, Ophthalmology & CMO | $1,544,742 | Mixed | 03 Feb 2022 | ||
| Todd Anderman | Chief Legal Officer | $1,024,128 | -$87,363 | -7.9% | Filing P/S | 08 Oct 2026 |
| Charles M. Warden | Director | $850,930 | Mixed | 10 Jun 2026 | ||
| Philip C. Strassburger | General Counsel | $784,856 | Filing P/S | 03 Feb 2024 | ||
| Rabia Gurses Ozden | Chief Medical Officer | $743,842 | Filing P/S | 03 Feb 2024 | ||
| Christopher G. White | Chief Business Officer | $601,129 | Filing P/S | 03 Feb 2024 | ||
| Jason Shand Robins | Chief Financial Officer | $576,781 | Mixed | 10 Jun 2026 | ||
| Leslie J. Williams | Director | $554,217 | Mixed | 10 Jun 2026 |
Recent insider transactions for OCULAR THERAPEUTIX, INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Todd Anderman | OCUL | Common Stock | Sale | -7.86% | $87,363 | $7.29 | -11,984 | 140,484 | 08 Oct 2026 | Direct |
| Peter Kaiser | OCUL | Common Stock | Sale | -3.78% | $70,430 | $7.05 | -9,990 | 254,388 | 02 Oct 2026 | Direct |
| Jeffrey S. Heier | OCUL | Common Stock | Sale | -3.41% | $76,626 | $7.05 | -10,869 | 307,457 | 02 Oct 2026 | Direct |
| Donald Notman | OCUL | Common Stock | Sale | -0.3% | $11,254 | $10.24 | -1,099 | 366,529 | 31 Aug 2026 | Direct |
| Pravin Dugel | OCUL | Common Stock | Gift | 7.21% | 50,092 | 744,903 | 25 Aug 2026 | By Pravin Dugel 2024 Irrevocable Trust | ||
| Pravin Dugel | OCUL | Common Stock | Gift | -100% | -50,092 | 0 | 25 Aug 2026 | By spouse | ||
| Peter Kaiser | OCUL | Common Stock | Sale | -1.13% | $32,687 | $10.77 | -3,035 | 264,378 | 24 Aug 2026 | Direct |
| Sanjay Nayak | OCUL | Common Stock | Sale | -0.58% | $20,450 | $10.78 | -1,897 | 326,898 | 24 Aug 2026 | Direct |
| Jeffrey S. Heier | OCUL | Common Stock | Sale | -1.02% | $35,531 | $10.78 | -3,296 | 318,326 | 24 Aug 2026 | Direct |
| Pravin Dugel | OCUL | Common Stock | Sale | -0.85% | $233,160 | $10.77 | -21,649 | 2,525,429 | 24 Aug 2026 | Direct |
| Pravin Dugel | OCUL | Common Stock | Gift | 50,092 | 50,092 | 16 Jun 2026 | By spouse | |||
| Pravin Dugel | OCUL | Common Stock | Gift | -1.93% | -50,092 | 2,547,078 | 16 Jun 2026 | Direct | ||
| Charles M. Warden | OCUL | Common Stock | Award | 16.2% | 14,000 | 100,464 | 10 Jun 2026 | Direct | ||
| Charles M. Warden | OCUL | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 10 Jun 2026 | Direct | |||
| Adrienne L. Graves | OCUL | Common Stock | Award | 28% | 14,000 | 64,000 | 10 Jun 2026 | Direct | ||
| Adrienne L. Graves | OCUL | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 10 Jun 2026 | Direct | |||
| Jason Shand Robins | OCUL | Common Stock | Award | 29.3% | 15,441 | 68,097 | 10 Jun 2026 | Direct | ||
| Jason Shand Robins | OCUL | Stock Option (Right to Buy) | Award | 14,024 | 14,024 | 10 Jun 2026 | Direct | |||
| Seung Suh Hong | OCUL | Common Stock | Award | 29.8% | 14,000 | 60,933 | 10 Jun 2026 | Direct | ||
| Seung Suh Hong | OCUL | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 10 Jun 2026 | Direct | |||
| Richard L. Lindstrom MD | OCUL | Common Stock | Award | 5.67% | 14,000 | 260,933 | 10 Jun 2026 | Direct | ||
| Richard L. Lindstrom MD | OCUL | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 10 Jun 2026 | Direct | |||
| Merilee Raines | OCUL | Common Stock | Award | 29.8% | 14,000 | 60,933 | 10 Jun 2026 | Direct | ||
| Merilee Raines | OCUL | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 10 Jun 2026 | Direct | |||
| Leslie J. Williams | OCUL | Common Stock | Award | 27.2% | 14,000 | 65,433 | 10 Jun 2026 | Direct | ||
| Leslie J. Williams | OCUL | Stock Option (Right to Buy) | Award | 44,000 | 44,000 | 10 Jun 2026 | Direct | |||
| Nadia Waheed | OCUL | Common Stock | Sale | -4.71% | $122,628 | $8.27 | -14,828 | 300,079 | 03 Jun 2026 | Direct |
| Pravin Dugel | OCUL | Common Stock | Gift | 131.5% | 394,696 | 694,811 | 28 May 2026 | By Pravin Dugel 2024 Irrevocable Trust | ||
| Pravin Dugel | OCUL | Common Stock | Gift | -100% | -394,696 | 0 | 28 May 2026 | By spouse | ||
| Pravin Dugel | OCUL | Common Stock | Sale | -0.81% | $173,479 | $8.20 | -21,156 | 2,597,170 | 26 May 2026 | Direct |
| Peter Kaiser | OCUL | Common Stock | Sale | -1.1% | $24,329 | $8.20 | -2,967 | 266,141 | 26 May 2026 | Direct |
| Jeffrey S. Heier | OCUL | Common Stock | Sale | -0.93% | $24,748 | $8.20 | -3,018 | 320,350 | 26 May 2026 | Direct |
| Sanjay Nayak | OCUL | Common Stock | Sale | -0.56% | $15,236 | $8.20 | -1,858 | 328,795 | 26 May 2026 | Direct |
| Pravin Dugel | OCUL | Common Stock | Gift | 394,696 | 394,696 | 09 Apr 2026 | By spouse | |||
| Pravin Dugel | OCUL | Common Stock | Gift | -13.1% | -394,696 | 2,618,326 | 09 Apr 2026 | Direct | ||
| Pravin Dugel | OCUL | Common Stock | Sale | -0.66% | $166,064 | $8.28 | -20,056 | 3,013,022 | 23 Feb 2026 | Direct |
| Peter Kaiser | OCUL | Common Stock | Sale | -1.03% | $23,267 | $8.28 | -2,810 | 269,108 | 23 Feb 2026 | Direct |
| Jeffrey S. Heier | OCUL | Common Stock | Sale | -0.94% | $25,312 | $8.28 | -3,057 | 323,368 | 23 Feb 2026 | Direct |
| Sanjay Nayak | OCUL | Common Stock | Sale | -0.53% | $14,565 | $8.28 | -1,759 | 330,653 | 23 Feb 2026 | Direct |
| Nadia Waheed | OCUL | Common Stock | Sale | -1.1% | $27,167 | $7.74 | -3,510 | 314,907 | 20 Feb 2026 | Direct |
| Richard L. Lindstrom MD | OCUL | Common Stock | Purchase | 32.3% | $461,354 | $7.66 | 60,229 | 246,933 | 20 Feb 2026 | Direct |
| Donald Notman | OCUL | Common Stock | Sale | -3.03% | $103,472 | $9.04 | -11,446 | 366,356 | 12 Feb 2026 | Direct |
| Sanjay Nayak | OCUL | Common Stock | Sale | -3.02% | $93,546 | $9.04 | -10,348 | 332,412 | 12 Feb 2026 | Direct |
| Pravin Dugel | OCUL | Common Stock | Sale | -3.95% | $1,128,933 | $9.04 | -124,882 | 3,033,078 | 12 Feb 2026 | Direct |
| Nadia Waheed | OCUL | Common Stock | Sale | -2.41% | $71,082 | $9.04 | -7,863 | 318,417 | 12 Feb 2026 | Direct |
| Donald Notman | OCUL | Common Stock | Sale | -1.57% | $51,539 | $8.54 | -6,035 | 377,802 | 04 Feb 2026 | Direct |
| Donald Notman | OCUL | Common Stock | Sale | -1.4% | $49,859 | $9.14 | -5,455 | 383,837 | 02 Feb 2026 | Direct |
| David Wayne Robinson | OCUL | Common Stock | Award | 136,000 | 136,000 | 21 Jan 2026 | Direct | |||
| David Wayne Robinson | OCUL | Stock Option (Right to Buy) | Award | 416,000 | 416,000 | 21 Jan 2026 | Direct | |||
| Jason Shand Robins | OCUL | Stock Option (Right to Buy) | Award | 33,000 | 33,000 | 20 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.